本文へ移動
AiSeekAiSeek
サインイン

企業

Retension Pharmaceuticals, Inc.

フォロー構造マップを開くこれについて質問この企業をリサーチ

概要

本社
US

Retension Pharmaceuticals, Inc. の構造

Retension Pharmaceuticals, Inc.

企業

関連 4 件
上流供給と依存
関係の開始2026
Retension Pharmaceuticals, Inc.企業 · 関連 4 件
第 1 層

上流供給と依存4

関係

矢印は関係の方向を示します。分野で絞り込めます。

  • Leerink Partnersにサービス提供 →Retension Pharmaceuticals, Inc.
    企業 · Leerink Partners根拠 1
    事実90%
    証拠を見る
    • 企業開示GlobeNewswire public company news2026-10-09 09:35
      Leerink Partners, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunning managers for the offering.
      出典を見る
  • Guggenheim Securitiesにサービス提供 →Retension Pharmaceuticals, Inc.
    企業 · Guggenheim Securities根拠 1
    事実90%
    証拠を見る
    • 企業開示GlobeNewswire public company news2026-10-09 09:35
      Leerink Partners, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunning managers for the offering.
      出典を見る
  • Oppenheimer & Co.にサービス提供 →Retension Pharmaceuticals, Inc.
    企業 · Oppenheimer & Co.根拠 1
    事実90%
    証拠を見る
    • 企業開示GlobeNewswire public company news2026-10-09 09:35
      Leerink Partners, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunning managers for the offering.
      出典を見る
  • Titan Partnersにサービス提供 →Retension Pharmaceuticals, Inc.
    企業 · Titan Partners根拠 1
    事実90%
    証拠を見る
    • 企業開示GlobeNewswire public company news2026-10-09 09:35
      Titan Partners is acting as lead manager for the offering.
      出典を見る

4 件中 1 から 4 件を表示

主張

出典とともに結論を確認し、項目を開いて証拠を読めます。

事実根拠 1
public offering size$45 million

公開できる証拠の概要はありません。

BioPharma Dive · 2026-10-09 18:59

証拠を見る
事実根拠 1
initial public offering price$12.00 per share

at an initial public offering price of $12.00 per share

GlobeNewswire public company news · 2026-10-09 09:35

証拠を見る
  • 企業開示GlobeNewswire public company news2026-10-09 09:35
    at an initial public offering price of $12.00 per share
    出典を見る
事実根拠 1
expected gross proceeds$45.0 million

The gross proceeds to Retension from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Retension, are expected to be $45.0 million.

GlobeNewswire public company news · 2026-10-09 09:35

証拠を見る
  • 企業開示GlobeNewswire public company news2026-10-09 09:35
    The gross proceeds to Retension from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Retension, are expected to be $45.0 million.
    出典を見る
事実根拠 1
underwriters option term30-day

Retension has granted the underwriters a 30-day option

GlobeNewswire public company news · 2026-10-09 09:35

証拠を見る
  • 企業開示GlobeNewswire public company news2026-10-09 09:35
    Retension has granted the underwriters a 30-day option
    出典を見る
事実根拠 1
additional shares available under underwriters option562,500 shares

option to purchase up to an additional 562,500 shares of its common stock

GlobeNewswire public company news · 2026-10-09 09:35

証拠を見る
  • 企業開示GlobeNewswire public company news2026-10-09 09:35
    option to purchase up to an additional 562,500 shares of its common stock
    出典を見る
事実根拠 1
initial public offering shares3,750,000 shares

pricing of its upsized initial public offering of 3,750,000 shares of its common stock

GlobeNewswire public company news · 2026-10-09 09:35

証拠を見る
  • 企業開示GlobeNewswire public company news2026-10-09 09:35
    pricing of its upsized initial public offering of 3,750,000 shares of its common stock
    出典を見る

10 件中 1 から 6 件を表示

市場とバリュエーション

バリュエーションは Pro と Research で利用できます。

Pro で解放

利用できません: 企業シグナル · 財務 · 開示資料 · ガイダンス